CwynKate Profile Banner
Kate Cwynarski Profile
Kate Cwynarski

@CwynKate

Followers
3K
Following
10K
Media
151
Statuses
3K

#Lymphoma @UCLH. Hon Associate Professor UCL. Chair UK T cell lymphoma working group. Past chair UK CNSL study group. views my own. #WiL #lymsm

London, England
Joined June 2017
Don't wanna be here? Send us removal request.
@CwynKate
Kate Cwynarski
3 days
Replacing microglia to treat a brain disease. replacing microglia cont CSF1R mutation with wild-type BM–derived cells can arrest disease progression in ALSP mouse models & human patients, underscoring therapeutic promise of microglial replacement therapy
1
0
1
@CwynKate
Kate Cwynarski
5 days
RT @WomenInLymphoma: Save the date! Our next webinar series will run throughout July - stay tuned for updates
Tweet media one
0
5
0
@CwynKate
Kate Cwynarski
5 days
RT @WomenInLymphoma: Pathogens and Lymphoma webinar series starts tomorrow - EBV and lymphomagenesis with Marie Donzel, @jenamengual, Amira….
0
4
0
@CwynKate
Kate Cwynarski
5 days
RT @YLeyfman: 🎥 MedNews Week x OncLive x Women in Lymphoma Present:. 🌟 Voices in Lymphoma: Women Shaping Care 🌟. 💡 Follicular Lymphoma: Gen….
0
5
0
@CwynKate
Kate Cwynarski
5 days
RT @mana1981: Thrilled to share our 3‑year follow‑up results from the phase III TRANSFORM trial of lisocabtagene maraleucel vs standard of….
0
10
0
@CwynKate
Kate Cwynarski
5 days
RT @DrRaulCordoba: #Hematology Immunological consequences of #CARTcell therapy: an analysis of infectious complications and immune reconsti….
0
18
0
@CwynKate
Kate Cwynarski
5 days
RT @AnneKniselyMD: Thrilled to share our paper now out in @Nature that correlates inactivating PPP2R1A somatic mutations with improved surv….
0
18
0
@CwynKate
Kate Cwynarski
5 days
RT @LabWaggoner: Preprint: Multimodal induction of fulminant HLH by IL-18 includes virus-specific NK immunodeficiency @canna_lab @varghese_….
0
5
0
@CwynKate
Kate Cwynarski
5 days
RT @DrRaulCordoba: #Hematology Outcomes of Allogeneic HCT in #Hodgkin #Lymphoma in the Era of Checkpoint Inhibitors: A Joint ⁦@CIBMTR⁩ and….
0
9
0
@CwynKate
Kate Cwynarski
10 days
RT @lymphomahub: Catch up on the latest developments in lymphoma and CLL with our coverage from the #18ICML Congress, June 17–21, 2025, Lug….
0
1
0
@CwynKate
Kate Cwynarski
10 days
RT @BrJHaem: Magrolimab, an anti-CD47 antibody, combined with obinutuzumab and venetoclax, is safe and induces durable responses in relapse….
0
13
0
@CwynKate
Kate Cwynarski
10 days
RT @Cure_FL: Fresh from #ICML2025 💜. Prof Jessica Okosun outlines key #FollicularLymphoma findings:. - Tafasitamab + R2 gets FDA approval.-….
0
7
0
@CwynKate
Kate Cwynarski
10 days
RT @Cancer_Cell: Online Now: Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention https….
0
7
0
@CwynKate
Kate Cwynarski
12 days
RT @BloodCancerJnl: Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell….
0
2
0
@CwynKate
Kate Cwynarski
12 days
RT @DengYanxiang: Our spatial FFPE-ATAC-seq is now published in @NatureComms! With extensive optimizations, it performs well across diverse….
0
53
0
@CwynKate
Kate Cwynarski
12 days
RT @EricTopol: Cancer chemotherapy does a number (as in mutations) to blood cells.2 new reports using single-cell sequencing show the delet….
0
35
0
@CwynKate
Kate Cwynarski
12 days
RT @CARTTherapy: Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: R….
0
11
0
@CwynKate
Kate Cwynarski
12 days
RT @ProfChrisPFox: Big thanks to a great team behind this novel & ambitious study.@Jessica_Okosun @CwynKate @graham_mcilroy @MartinezCalleM….
0
2
0
@CwynKate
Kate Cwynarski
12 days
RT @graham74GC: It’s back and it’s online. The fantastic #lymphomaManagement course. With much thanks to @LymphomaAction for their suppor….
0
7
0
@CwynKate
Kate Cwynarski
17 days
Association of Epstein-Barr virus genomic alterations with human pathologies | Blood | American Society of Hematology
0
4
22